ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade

The purpose of this study is to compare the effectiveness of 6 months of HER2-targeted medications (trastuzumab with or without pertuzumab) versus 12 months of HER2-targeted medications at reducing the risk of breast cancer coming back or death in patients with early-stage HER2+ breast cancer who...